Emerging challenges for psychedelic therapy

Robin Carhart-Harris and colleagues have written this piece for JAMA Psychiatry. They comment: "Following decades of prohibition, psychedelic drugs are returning to mainstream psychiatry and neuroscience. When paired with psychotherapy and administered in a supportive context, so-called psychedelic therapy shows promise in treating depression, anxiety, substance misuse, and end-of-life distress. Large therapeutic effect sizes and positive safety outcomes in clinical trials have led to a remarkable surge in scientific, commercial, regulatory, and public interest. Despite this enthusiasm, much remains unknown about psychedelic drugs, and distinct challenges have emerged with the field’s increase. We aim to frame these challenges with 4 fundamental questions."

For more psychedelic news and research, visit the psychedelic health professional network homepage.